As the January 1 implementation date approaches, here is a quick guide to the controversial new rebate model for the 340B Drug Pricing Program and the legal battle to stop it.

The AHA and several safety-net providers argue that an upcoming mandatory rebate pilot violates administrative law, imposes millions in costs, and threatens patient care in vulnerable communities.

Since 1992, the 340B drug discount program has entitled certain federal grantee clinics and hospitals (called “covered entities”) to purchase outpatient drugs at substantial discounts. The discounted ...

Hospital groups raise issues with 340B rebate pilot program citing cash flow, administrative costs, and unclear rebate denials risks.

Healthcare policy changes may increase uncompensated care, stressing hospitals and the 340B program, crucial for subsidizing low-income patient care. The 340B rebate model, starting in 2026, could ...

Hospitals are suing to block a Trump administration pilot that will allow drugmakers to issue post-sale rebates instead of upfront discounts on medications in the 340B drug discount program, arguing ...

The federal agency overseeing the controversial 340B Rebate Model Pilot Program has “vastly underestimated” how much time and money hospitals obligated to participate will spend on reporting burdens, ...

With HRSA's approval of eight manufacturer rebate plans, hospitals enter the 60-day readiness period before the January 1, 2026, launch. DEERFIELD BEACH, Fla., Oct. 31, 2025 /PRNewswire/ -- The ...

St. Mary's in Lewiston is a plaintiff in the suit, which targets a pilot program introduced by the Trump administration.